BCAL Diagnostics Ltd
BDX
Company Profile
Business description
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.
Contact
Queen Victoria Building
GPO Box Q128
SydneyNSW1230
AUSSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,816.40 | 58.90 | -0.66% |
| CAC 40 | 7,774.85 | 8.64 | 0.11% |
| DAX 40 | 24,200.10 | 139.81 | 0.58% |
| Dow JONES (US) | 44,023.29 | 436.36 | -0.98% |
| FTSE 100 | 8,971.03 | 32.71 | 0.37% |
| HKSE | 24,517.76 | 72.36 | -0.29% |
| NASDAQ | 20,677.80 | 37.47 | 0.18% |
| Nikkei 225 | 39,663.40 | 14.62 | -0.04% |
| NZX 50 Index | 12,754.59 | 64.96 | 0.51% |
| S&P 500 | 6,243.76 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,561.80 | 68.50 | -0.79% |
| SSE Composite Index | 3,503.78 | 1.22 | -0.03% |